Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials
Bokemeyer, Carsten × Van Cutsem, Eric Rougier, Philippe Ciardiello, Fortunato Heeger, Steffen Schlichting, Michael Celik, Ilhan Köhne, Claus-Henning #
European Journal of Cancer vol:48 issue:10 pages:1466-1475
The CRYSTAL and OPUS randomised clinical trials demonstrated that adding cetuximab to first-line chemotherapy in patients with KRAS wild-type metastatic colorectal cancer (mCRC) significantly improved treatment outcome compared with chemotherapy alone. The objective of this pooled analysis was to further investigate these findings in patients with KRAS wild-type tumours using extended survival data and following an enhancement in the ascertainment rate of KRAS and BRAF tumour mutation status from these studies.